

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Adalimumab for treating moderate to severe hidradenitis suppurativa

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
| No equality issues were identified during the scoping process. |

- | |
|---|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
| Issues raised in the submissions and expert statements: <ul style="list-style-type: none">• Hidradenitis suppurativa is more common in people of African family origin.• Hidradenitis suppurativa affects genders differently and difficulties with personal appearance and mental health are more likely to be dismissed if the person is male.<ul style="list-style-type: none">○ <i>The Committee will not discriminate between male and female patients or people of different ethnic background, and will ensure that any recommendations do not discriminate against any groups protected under the Equality Act.</i>• It may be difficult for people with a phobia of needles to take adalimumab.<ul style="list-style-type: none">○ <i>There is no other way of taking adalimumab, so the Committee's recommendations cannot address this issue.</i>• Many people with the condition have other disabilities.<ul style="list-style-type: none">○ <i>The Committee considered whether its recommendations could have a different impact on people with a disability than on the wider population. As it was minded not to recommend adalimumab, the Committee agreed that all people would be</i> |

affected equally, regardless of disability.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable (minded no)

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, at the end of in chapter 4: "The committee considered whether its preliminary recommendations were associated with any issues related to the equality legislation and the requirement for fairness. The committee discussed comments from patient and professional organisations indicating

that prevalence is greater in people of African family origin and in women, and some people with hidradenitis suppurativa have other disabilities; these characteristics are protected under the Equality Act 2010. The committee agreed that, because all people would be affected equally by its recommendations, there was no unfairness to any protected group.”

Approved by Associate Director (name): Helen Knight

Date: 12/02/2016

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendation changed from a minded no to a yes. Because all people will be affected equally by the committee's recommendations, there is no unfairness to any protected group

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, at the end of section 4

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 28/04/2016